Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 19;14:2861. doi: 10.1038/s41467-023-38581-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Western blot for ADAR1 and SCD1 expression in GX006 parental organoids with or without ADAR1 overexpressed and with or without SCD1 concomitantly repressed. b–d CellTiter-Glo analysis of cell viability (b), Annexin V-PI analysis of apoptotic cells (c) and in vitro limiting dilution spheroid formation and tumor-initiating cell frequency calculation (d) in GX006 parental organoid lines with or without ADAR1 overexpressed and with or without SCD1 concomitantly repressed. e Western blot for ADAR1 and SCD1 expression in GX006 parental and GX006 5FU + CDDP resistant organoid lines with or without ADAR1 repressed and with or without SCD1 concomitantly overexpressed. Images representative of n = 3 independent experiments. f–h CellTiter-Glo analysis of cell viability (f), Annexin V-PI analysis of apoptotic cells (g) and in vitro limiting dilution spheroid formation and tumor-initiating cell frequency calculation (h) GX006 parental and GX006 5FU + CDDP resistant organoid lines with or without ADAR1 repressed and with or without SCD1 concomitantly overexpressed. i Schematic diagram of treatment regimen comparing GX006 parental and GX006 5FU + CDDP resistant organoid lines with or without ADAR1 repressed and with or without SCD1 concomitantly overexpressed injected into NSG mice subcutaneously. j, k Volume (j) and weight (k) of tumors derived from the indicated cell lines at end point. l Waterfall plot showing the response of each tumor in each group at end point. m Ex vivo limiting dilution assay of tumors harvested from each group to evaluate tumor-initiating cell frequency. (a–h) n = 3 independent experiments; (i–m) n = 10–12 mice. Significance were calculated by (b, f, j) two-way ANOVA; (c, g, k, l) by one-way ANOVA; (d, h, m) by one-sided extreme limiting dilution analysis. Data was presented as mean ± standard deviation. EV for empty vector control, NTC for non-target control, OE for overexpression, SCD1 KD1 and KD2 for SCD1 shRNA knockdown (clones 1 and 2), ADAR1 KD for ADAR1 shRNA knockdown (clone 1). ns for not significant. Source data are provided as a Source Data file. Illustration for (i) was created using BioRender.com.